Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.

Disclosure: Employment/leadership position: None; Intellectual property rights/inventor/patent holder: None; Consultant/advisory role: D. Craig Allred, Genomic Health Clinic, DAKO, Pfizer; Honoraria: None; Research funding/contracted research: D. Craig Allred, Pfizer; Ownership interest: D. Craig Allred, Scientific Advisory Board of Clarient, Inc.; Expert testimony: None; Other: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers.